Perrigo Gains Most in 3 Months on UBS ‘Buy’ Rating
Perrigo Inc. climbed the most since September as the manufacturer of over-the-counter pharmaceuticals was rated “buy” in new coverage at UBS AG.
The shares rose 4.8 percent, the most since Sept. 15, to 234.5 shekels at the 4:30 p.m. close in Tel Aviv.
UBS set a share-price estimate of $72. The shares gained 2 percent to $64.12 in U.S. trading on Dec. 3.
To contact the reporter on this story: Claudia Maedler in Dubai at firstname.lastname@example.org
To contact the editor responsible for this story: Shanthy Nambiar at email@example.com